Ligand Pharma (LGND) Tops Q2 EPS by 29c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 --0%
Revenue Growth %: -32.2%
Financial Fact:
Income tax expense (benefit): -160K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Income tax expense (benefit): -160K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.63, $0.29 better than the analyst estimate of $1.34. Revenue for the quarter came in at $54.7 million versus the consensus estimate of $70.41 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
- Erste Group Starts Marsh (MRSH) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
